Skip to main content

Advertisement

Log in

Desensitisation of native and recombinant human urotensin-II receptors

  • ORIGINAL ARTICLE
  • Published:
Naunyn-Schmiedeberg's Archives of Pharmacology Aims and scope Submit manuscript

Abstract

Human urotensin-II (U-II) is an 11-amino-acid cyclic peptide that activates a Gq-coupled receptor named UT. Little is known about the desensitisation profile of this receptor as peptide binding is essentially irreversible. In the present study, we have examined the effects of U-II and carbachol on Ca2+ signalling in SJCRH30 rhabdomyosarcoma (receptor density, Bmax ~0.1 pmol/mg protein) and human embroynic kidney (HEK)hUT (B max ~1.4 pmol/mg protein) cells expressing native and recombinant UT, respectively. In SJCRH30, HEKhUT and human peripheral blood mononuclear cells induced to express native UT by treatment with 2 μg/ml lipopolysaccharide (LPS), we have measured the effects of U-II treatment on UT mRNA. In SJCRH30 cells, primary stimulation with carbachol (250 μM) did not affect a secondary challenge with U-II (1 μM) and primary challenge with U-II did not affect a secondary challenge with carbachol. In contrast, in HEKhUT cells, primary stimulation with carbachol (250 μM) reduced a secondary challenge to U-II (1 μM) by 84% and primary challenge with U-II reduced a secondary challenge to carbachol by 76%. Pre-treatment of SJCRH30 cells with U-II reduced UT mRNA after 6 h and this returned to basal after 24 h. In recombinant HEKhUT cells, UT mRNA expression increased following a 6 h treatment with 1 μM U-II. U-II treatment of naïve un-stimulated peripheral blood mononuclear cells was without effect. However, when UT expression is up-regulated following 15 h of LPS treatment, a 6 h U-II challenge reduced UT mRNA by 66%. In summary, we report differences in the desensitisation profiles of native and recombinant U-II receptors. Design and interpretation of functional experiments are hampered by irreversibility of U-II binding.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  • Ames RS, Sarau HM, Chambers JK, Willette RN, Aiyar NV, Romanic AM, Louden CS, Foley JJ, Sauermelch CF, Coatney RW, Ao Z, Disa J, Holmes SD, Stadel JM, Martin JD, Liu WS, Glover GI, Wilson S, McNulty DE, Ellis CE, Elshourbagy NA, Shabon U, Trill JJ, Hay DW, Douglas SA et al (1999) Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature 401:282–286

    Article  CAS  PubMed  Google Scholar 

  • Ancellin N, Preisser L, Le Maout S, Barbado M, Creminon C, Corman B, Morel A (1999) Homologous and heterologous phosphorylation of the vasopressin V1a receptor. Cell Signal 11:743–751

    Article  CAS  PubMed  Google Scholar 

  • Barnes TA, McDonald J, Rowbotham DJ, Duarte TL, Lambert DG (2007) Effects of receptor density on Nociceptin/OrphaninFQ peptide receptor desensitisation: studies using the ecdysone inducible expression system. Naunyn Schmiedebergs Arch Pharmacol 376:217–225

    Article  CAS  PubMed  Google Scholar 

  • Bern HA, Lederis K (1969) A reference preparation for the study of active substances in the caudal neurosecretory system of teleosts. J Endocrinol 45(Suppl):xi–xii

    PubMed  Google Scholar 

  • Brailoiu E, Jiang X, Brailoiu GC, Yang J, Chang JK, Wang H, Dun NJ (2008) State-dependent calcium mobilization by urotensin-II in cultured human endothelial cells. Peptides 29:721–726

    Article  CAS  PubMed  Google Scholar 

  • Bundey RA, Nahorski SR (2001) Homologous and heterologous uncoupling of muscarinic M(3) and alpha(1B) adrenoceptors to Galpha(q/11) in SH-SY5Y human neuroblastoma cells. Br J Pharmacol 134:257–264

    Article  CAS  PubMed  Google Scholar 

  • Camarda V, Rizzi A, Calo G, Gendron G, Perron SI, Kostenis E, Zamboni P, Mascoli F, Regoli D (2002) Effects of human urotensin II in isolated vessels of various species; comparison with other vasoactive agents. Naunyn Schmiedebergs Arch Pharmacol 365:141–149

    Article  CAS  PubMed  Google Scholar 

  • Chen YL, Liu JC, Loh SH, Chen CH, Hong CY, Chen JJ, Cheng TH (2008) Involvement of reactive oxygen species in urotensin II-induced proliferation of cardiac fibroblasts. Eur J Pharmacol 593:24–29

    Article  CAS  PubMed  Google Scholar 

  • Chomczynski P, Sacchi N (1987) Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162:156–159

    Article  CAS  PubMed  Google Scholar 

  • Cosenzi A (2008) Non peptidic urotensin II antagonists: perspectives for a new class of drugs. Cardiovasc Hematol Agents Med Chem 6:80–91

    Article  CAS  PubMed  Google Scholar 

  • Douglas SA, Ashton DJ, Sauermelch CF, Coatney RW, Ohlstein DH, Ruffolo MR, Ohlstein EH, Aiyar NV, Willette RN (2000) Human urotensin-II is a potent vasoactive peptide: pharmacological characterization in the rat, mouse, dog and primate. J Cardiovasc Pharmacol 36:S163–S166

    CAS  PubMed  Google Scholar 

  • Douglas SA, Dhanak D, Johns DG (2004a) From ‘gills to pills’: urotensin-II as a regulator of mammalian cardiorenal function. Trends Pharmacol Sci 25:76–85

    Article  CAS  PubMed  Google Scholar 

  • Douglas SA, Naselsky D, Ao Z, Disa J, Herold CL, Lynch F, Aiyar NV (2004b) Identification and pharmacological characterization of native, functional human urotensin-II receptors in rhabdomyosarcoma cell lines. Br J Pharmacol 142:921–932

    Article  CAS  PubMed  Google Scholar 

  • Filipeanu CM, Brailoiu E, Le Dun S, Dun NJ (2002) Urotensin-II regulates intracellular calcium in dissociated rat spinal cord neurons. J Neurochem 83:879–884

    Article  CAS  PubMed  Google Scholar 

  • Fontes-Sousa AP, Brás-Silva C, Pires AL, Monteiro-Sousa D, Leite-Moreira AF (2007) Urotensin II acutely increases myocardial length and distensibility: potential implications for diastolic function and ventricular remodeling. Naunyn Schmiedebergs Arch Pharmacol 376:107–115

    Article  CAS  PubMed  Google Scholar 

  • Grynkiewicz G, Poenie M, Tsien RY (1985) A new generation of Ca2+ indicators with greatly improved fluorescence properties. J Biol Chem 260:3440–3450

    CAS  PubMed  Google Scholar 

  • Hirst RA (2006) Measurement of [Ca2+]i in whole cell suspensions using fura-2. Methods Mol Biol 312:37–45

    PubMed  Google Scholar 

  • Leprince J, Chatenet D, Dubessy C, Fournier A, Pfeiffer B, Scalbert E, Renard P, Pacaud P, Oulyadi H, Segalas-Milazzo I, Guilhaudis L, Davoust D, Tonon MC, Vaudry H (2008) Structure-activity relationships of urotensin II and URP. Peptides 29:658–673

    Article  CAS  PubMed  Google Scholar 

  • Lescot E, Bureau R, Rault S (2008) Nonpeptide urotensin-II receptor agonists and antagonists: review and structure-activity relationships. Peptides 29:680–690

    Article  CAS  PubMed  Google Scholar 

  • McDonald J, Barnes TA, Okawa H, Williams J, Calo G, Rowbotham DJ, Lambert DG (2003) Partial agonist behaviour depends upon the level of nociceptin/orphanin FQ receptor expression: studies using the ecdysone-inducible mammalian expression system. Br J Pharmacol 140:61–70

    Article  CAS  PubMed  Google Scholar 

  • McDonald J, Batuwangala M, Lambert DG (2007) Role of urotensin II and its receptor in health and disease. J Anesth 21:378–389

    Article  PubMed  Google Scholar 

  • Mellstrom B, Savignac M, Gomez-Villafuertes R, Naranjo JR (2008) Ca2+-operated transcriptional networks: molecular mechanisms and in vivo models. Physiol Rev 88:421–449

    Article  CAS  PubMed  Google Scholar 

  • Mundell SJ, Pula G, More JC, Jane DE, Roberts PJ, Kelly E (2004) Activation of cyclic AMP-dependent protein kinase inhibits the desensitization and internalization of metabotropic glutamate receptors 1a and 1b. Mol Pharmacol 65:1507–1516

    Article  CAS  PubMed  Google Scholar 

  • Onan D, Hannan RD, Thomas WG (2004) Urotensin II: the old kid in town. Trends Endocrinol Metab 15:175–182

    Article  CAS  PubMed  Google Scholar 

  • Pahl HL (1999) Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 18:6853–6866

    Article  CAS  PubMed  Google Scholar 

  • Russell FD, Molenaar P (2004) Cardiovascular actions of human urotensin II—considerations for hypertension. Naunyn Schmiedebergs Arch Pharmacol 369:271–273

    Article  CAS  PubMed  Google Scholar 

  • Segain JP, Rolli-Derkinderen M, Gervois N, Raingeard de la Bletiere D, Loirand G, Pacaud P (2007) Urotensin II is a new chemotactic factor for UT receptor-expressing monocytes. J Immunol 179:901–909

    CAS  PubMed  Google Scholar 

  • Song W, McDonald J, Camarda V, Calo G, Guerrini R, Marzola E, Thompson JP, Rowbotham DJ, Lambert DG (2006) Cell and tissue responses of a range of Urotensin II analogs at cloned and native urotensin II receptors. Evidence for coupling promiscuity. Naunyn Schmiedebergs Arch Pharmacol 373:148–157

    Article  CAS  PubMed  Google Scholar 

  • Sprague J, Harrison C, Rowbotham DJ, Smart D, Lambert DG (2001) Temperature-dependent activation of recombinant rat vanilloid VR1 receptors expressed in HEK293 cells by capsaicin and anandamide. Eur J Pharmacol 423:121–125

    Article  CAS  PubMed  Google Scholar 

  • Sue YM, Chen CH, Hsu YH, Hou CC, Cheng CY, Chen YC, Lin SL, Chen TW, Chen TH (2009) Urotensin II induces transactivation of the epidermal growth factor receptor via transient oxidation of SHP-2 in the rat renal tubular cell line NRK-52E. Growth Factors 27:155–162

    Article  CAS  PubMed  Google Scholar 

  • Williams JP, Thompson JP, McDonald J, Barnes TA, Cote T, Rowbotham DJ, Lambert DG (2007) Human peripheral blood mononuclear cells express nociceptin/orphanin FQ, but not mu, delta, or kappa opioid receptors. Anesth Analg 105:998–1005 table of contents

    Article  CAS  PubMed  Google Scholar 

  • Williams JP, Thompson JP, Rowbotham DJ, Lambert DG (2008) Human peripheral blood mononuclear cells produce pre-pro-nociceptin/orphanin FQ mRNA. Anesth Analg 106:865–866 table of contents

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

MB holds a Leicester-Ferrara International PhD studentship. PCR equipment was provided by a grant from British Journal of Anaesthesia / Royal College of Anaesthetists. This paper is dedicated to the memory of Stephen A. Douglas, an outstanding ‘Urotensin scientist’ and a good friend.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to David G. Lambert.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Batuwangala, M.S., Calo, G., Guerrini, R. et al. Desensitisation of native and recombinant human urotensin-II receptors. Naunyn-Schmied Arch Pharmacol 380, 451–457 (2009). https://doi.org/10.1007/s00210-009-0441-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00210-009-0441-9

Keywords

Navigation